Grace Capital’s Editas Medicine EDIT Stock Holding History

Grace Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-111	Closed	-$3K	–	241
2020 Q2	$3K	Hold	111	–	–	﹤0.01%	214
2020 Q1	$2K	Hold	111	–	–	﹤0.01%	180
2019 Q4	$3K	Buy	+111	New	+$2.77K	﹤0.01%	193
2018 Q3	–	Sell	-111	Closed	-$4K	–	216
2018 Q2	$4K	Buy	+111	New	+$3.93K	﹤0.01%	219

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Grace Capital's EDIT Position: Q3 2020 in Review

Grace Capital sold out of Editas Medicine (EDIT) in Q3 2020, closing a stake of 111 shares — an estimated $3K sold.

Grace Capital first reported a position in EDIT in Q2 2018 and held it in 4 quarters. The position peaked at $4K in Q2 2018. 239 funds tracked by Wall St. Rank hold EDIT as of Q3 2020.

Grace Capital reported no remaining Editas Medicine position as of Q3 2020 after selling out during the quarter.
Grace Capital sold 111 Editas Medicine shares in Q3 2020, an estimated $3K.
Grace Capital first reported a position in Editas Medicine in Q2 2018 and held it in 4 quarters.
Grace Capital's Editas Medicine position peaked at $4K in Q2 2018.
239 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2020.

Based on Grace Capital's 13F filing for Q3 2020, filed 12 Nov 2020.